insitro Presents Data at ADA 86th Scientific Sessions Showing AI-Discovered MASH Candidate Has Anti-Fibrotic Signal Beyond Liver-Fat Reduction

Summary

Share - Findings from insitro’s lead therapeutic CTRO-1013 program demonstrate that liver-targeted silencing of IRS1 lowered circulatory biomarkers associated with fibrosis progression and hepatocyte injury in an industry-standard fibrogenic preclinical mouse model of MASH - Data presented today at ADA provide converging evidence from human genetics and preclinical models supporting IRS1’s effect on liver fat and liver fibrosis - The findings extend insitro’s AI-driven discovery of IRS1 – the strongest of 480 genetic signals for liver fat – and support the development of CTRO-1013 toward first-in-human trials this year NEW ORLEANS – June 8, 2026 – insitro, the physical AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) therapeutic development program during a podium presentation at the American Diabetes Association (ADA) 86th Scientific Sessions. The data demonstrate that liver-targeted silencing of IRS1 reduced fibrosis progression and injury-associated circulatory biomarkers in an industry-standard fibrogenic preclinical mouse model, with effects that appear partly independent of reductions in liver fat. The findings support the continued advancement of CTRO-1013, the company’s liver-targeted IRS1 candidate, through IND-enabling studies toward first-in-human trials this year. The presentation, “Hepatic IRS1 as a Therapeutic Target in MASLD: AI/ML Driven Genetic Discovery and In Vivo Therapeutic Validation,” was delivered by Santhosh Satapati, Ph.D., Senior Director of Metabolic Diseases at insitro. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease marked by excess fat accumulation in the liver. MASH is the progressive form of MASLD in which fat accumulation is accompanied by inflammation, liver injury, and fibrosis. Fibrosis – the scarring that can progress to cirrhosis, liver failure, and liver cancer – is one of the strongest predictors of poor outcomes for patients with MASH. Yet finding high-confidence targets has been difficult because the most relevant liver phenotypes, fibrosis among them, are hard to measure at the scale needed for human genetic discovery. Human genetic analyses revealed an IRS1-associated fibrosis signal that persists even after adjusting for liver fat, suggesting a fibrotic mechanism inde…